Print

RV 124

A Phase I, Dose-Ranging Trial of the Pasteur Merieux Connaught Oligomeric HIV-1 gp160MN/LAI-2 Vaccine Alone or Primed with Live Recombinant ALVAC-HIV (vCP205) in HIV Seronegative Adults

Trial Details:

I Completed
Walter Reed Army Institute of Research (WRAIR), April 16, 1998
ALVAC-HIV MN120TMG strain (vCP205),gp160MN/LAI-2
ALVAC-HIV MN120TMG strain (vCP205) Viral Vector - Pox
gp160MN/LAI-2 Protein
USA 0
http://www.clinicaltrials.gov; http://www.actis.org http://www.clinicaltrials.gov; http://www.actis.org